Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
  • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
  • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the invention in its broad aspects relates to caprolactam derivatives which are useful as angiotensin converting enzyme inhibitors and as antihypertensives.
• the compounds of this invention can be shown by the following formula: wherein
• the loweralkyl or lower alkenyl groups except where noted otherwise represented by any of the variables include straight and branched chain hydrocarbon radicals from one to six carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl or vinyl, allyl, butenyl and the like.
• Lower alkoxy means alkoxy containing 1-6 carbon atoms with the oxygen.
• the aralkyl groups represented by any of the above variables have from one to four carbon atoms in the alkyl portion thereof and include for example, benzyl, p-methoxy benzyl and the like.
• Halo means chloro, bromo, iodo or fluoro.
• Aryl where it appears in any of the radicals except where noted represents phenyl, naphthyl or biphenyl.
• Heteroaryl groups where they appear include for example pyridyl, thienyl, furyl, indolyl, benzthienyl, imidazoyl, thiazolyl and quinolinyl.
• Acylamino refers to lower alkanoylamino and aroylamino groups.
• the preferred, more preferred and most preferred compounds also include the pharmaceutically acceptable salts thereof.
• Lysine [or an ( ⁇ -substituted lysine (R2 H) which can be prepared by the procedure of Collinse et al., J. Am. Chem. Soc, 76, 2317 (1954) followed by that of Tull et al., J. Org. Chem. 29, 2425 (1964)] is converted to the N ⁇ -protected derivative II by methods known in the art.
• Suitable protecting groups R 8 include the phthalimido, t-butoxycarbonyl, and benzyloxycarbonyl groups.
• R 7 may be O H or alkoxy as the methods below require and R is as defined.
• Intermediate II is reductively coupled with the keto acid or ester III in aqueous solution, preferably near neutrality or in a suitable organic solvent, such as methanol or acetonitrile, in the presence of sodium cyanoborohydride or if protecting groups do not interefere with hydrogen and a suitable catalyst to yield IV.
• the blocking group R 8 is removed by appropriate known methods, and the resulting compound VI is reductively coupled with keto acid, ester, etc. VII to obtain I.
• Substituents at R and R 4 may be altered by standard methods if desired.
• Intermediate II may also be alkylated with a haloester such as VIII.
• suitable solvent such as DMF or methylene chloride.
• Other known peptide coupling methods may also be used if desired.
• XII - A p-toluenesulfonate ester
• XIII - A Br IV
• hydroxyaminoacid X [Gandry, Can. J. Res., 26B, 387 (1948)] is converted to the N-protected hydroxy acid XI by established techniques, then the terminal hydroxyl is activated by known methods such as conversion to the tosyl ester XII or to the bromide XIII. Reaction with amino acid XIV affords the intermediate IV, which may be converted to I as described above.
• Substituted caprolactams (R 2 ⁇ H), are conveniently prepared via Beckman ring expansion of the corresponding 2-substituted cyclohexanone oximes using standard reaction conditions. These caprolactams can then be halogenated and converted to 3-amino derivatives via displacement reactions described, for example, by Blacke, et al. and Tull, et al. above; Wineman, et al., J. Am. Chem. Soc. 80, 6233 (1958) and Francis et al., J. Am. Chem. Soc. 80, 6238 (1958).
• Aminolactams XV are then alkylated on the exocyclic nitrogen using reagents VII or IX by the methods described above to obtain XVI.
• a strong base such as sodium hydride in a solvent such as DMF or THF affords I.
• halocaprolactam XVII can also be alkylated with reagent VIII in the presence of a strong base such as sodium hydride in a suitable solvent such as DMF or THF to obtain the alkylated halolactam XVIII.
• a strong base such as sodium hydride
• a suitable solvent such as DMF or THF
• halocaprolactam XVII is reacted with the amino acid derivative XIX to obtain the intermediate XVI for conversion to I as described above.
• the carbon atoms to which, R l , R 2 and R 3 are attached and the ring carbon atom to which the fragment is attached may be asymmetric.
• the above described syntheses can utilize racemates, enantiomers or diastereomers as starting materials and intermediates.
• the diastereomeric products can be separated by chromatographic or fractional crystallization methods.
• racemic products result, they may be resolved by crystallization of salts of optically active acids or bases or by other methods known in the art.
• the asymmetric carbon atoms specified above may be in two configurations (S or R) and both are within the scope of this invention, although S is generally preferred except for the configurations at the carbon to which R 2 is attached as exemplified in specific compounds of this invention.
• the compounds of this invention form salts with various inortgauic and organic acids and bases which are also within the scope of the imvantion.
• Such salts include ammoniur salts, alkali metal salts like sodium and potassium salts, alkaline earth metal salts like the calcium and magnesium salts, salts with organic bases, e.g., dicyclohexylamina, N-methyl-D-glucamire, salts with amino acids like arginine, lysine and the like.
• salts with organic and inorganic acids may be prepared; e.g., HCl, HBr, H 2 SO 4 , H 3 PO 4 , methanesulfonic, toluenesulfonic, maleic, fumaric, camphorsulfonic acids.
• the non-toxic physiologically aceptable salts are particularly valuable, although other salrs are also useful, e.g., in isolating or purifying products.
• the salts may be formed by conventional means, as by reacting the free acid or free base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the cations of an existing salt for another cation on a suitable ion exchange resin.
• the compounds of chis invention inhibit angiotensin converting enzyme and thus block conversion of the decapeptide angiotensin I to angiotensin II.
• Angiotensin II is a potent presson Substance.
• blood-pressure lowering results for inhj itim of its brosyntheois especially in anima a and humans whose hypertension is angiotensin II related.
• converting enzyme degrades the vasodepressor substance, bradykinin. Therefore, inhibitors of angiotensin converting enzyme may lower blood pressure also by potentiation of bradykinin.
• inhibitors of angiotensin converting enzyme are effective antihypertensive agents in a variety of animal models and are useful clinically, for example, in many human patients with renovascular, malignant and essential hypertension. See, for example, D. W. Cushman et al., Biochemistry 16, 5484 (1977).
• the compounds of the invention are useful in treating hypertension. They are also of value in the management of acute and chronic congestive heart failure, in the treatment of secondary hyperaldosteronism, scleroderma, primary and secondary pulmonary hyertension, renal failure and renal vascular hypertension, and in the management of vascular disorders such as migraine.
• the application of the compounds of this invention for these and similar disorders will be apparent to those skilled in the art.
• the compounds of this invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, and the like.
• the compounds of this invention can be administered to- patients in need of such treatment in dosages that will provide optimal pharmaceutical efficacy.
• the dosage range will generally be about to 200 mg. per patient per day which can be administered in single or multiple doses.
• the dosage ranga will be about 2.5 to 10 mg per patient per day
• the compounds of this invention can be given in combination with such compounds as amiloride, atenolol, bendroflumethiazide, chlorothalidone, chlorothiazide, clonidine, cryptenamine acetates and cryptenamine tannates, deserpidine, diazoxide, guanethidene sulfate, hydralazine hydrochloride, hydrochlorothiazide, hydroflumethiazide, metolazone, metoprololtartate, methyclothiazide, methyldopa, methyldopate hydrochloride, minoxidil, (S)-1- ⁇ [2-(3,4-dimethoxyphenyl)ethyl]amino ⁇ -3- ⁇ [4-(2-thienyl)-lH-imida
• the individual daily dosages for these combinations can range from about one-fifth of the maximum recomended levels for the entities when they are given singly.
• one of the antihypertensives of this invention effective clinically in the 2.5-100 milligrams per day range can be effectively combined at levels at the 0.5-100 milligrams per day range with the following compounds at the indicated per day dose range: hydrochlorothiazide (10-100 mg), timolol (5-60 mg), methyl dopa (65-2000 mg) the pivaloyloxyethyl ester of methyl dopa (30-1000 mg) indacrinone and variable ratios of its enantiomers (25-150 mg) and (+)-4- ⁇ 3- ⁇ [2-(1-hydroxycyclohexyl)ethyl]-4-oxo-2-thiazolidiny ⁇ propy ⁇ -benzoic acid (10-100 mg).
• the triple drug combinations of hydrochlorothiazide (10-100 mg) plus timolol (5-60 mg) plus converting enzyme inhibitor of this invention (0.5-100 mg) or hydrochlorothiazide (10-100 mg) plus amiloride (5-20 mg) plus converting enzyme inhibitor of this invention (0.5-100 mg) are effective combinations to control blood pressure in hypertensive patients.
• these dose ranges can be adjusted on a unit basis as necessary to permit divided daily dosage and, as noted above, the dose will vary deponding on the nature and severity of the disease, weight of patient, special diets and other factors.
• these combinations can be formulated into pharmaceutical compositions as discussed below.
• a compound or mixture of compounds of Formula 1 or a physiologically acceptable salt is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practive.
• a physiologically acceptable vehicle carrier, excipient, binder, preservative, stabilizer, flavor, etc.
• the amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.
• Illustrative of the adjuvants which may be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as microcrystalline cellulose; a disintegrating agent such as corn starch, pregelatinized starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry.
• a liquid carrier such as fatty oil.
• tablets may be coated with shellac, sugar or both.
• a syrup or elixir may contain the active compund, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring suchas cherry or orange flavor.
• Sterile compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the active substance in a vehicle such a water for injection, a naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cottonseed oil, etc. or a synthetic fatty vehicle like ethyl oleate or the like. Buffers, preservatives, antioxidants and the like can be incorporated as required.
• esterification in HCl-ethanol affords 1-ethoxycarbonylmethyl-3-(S)-1-(1-ethoxycarbonyl-3-(3-indolyl)lpropyl)amino]-perhydroazepin-2-one.
• Mass Spectrum (as bistrimethylsilyl derivative): M + , 506; 491 (M + - CH 3 ) ; 391 (M + - CO 2 TMS) .
• Mass spectrum M+ 247; 212 (M+-Cl); 202 (M+ -C 2 H 5 O).
• Mass spectrum M+ 390; 372 (M+ - H 2 O); 361 (M+ - C 2 H 5 ) ; 345 (M+ OC 2 H 5 ).
• Mass spectrum M+ 362; 344 (M+ - H 2 O) ; 317 (M+-CO 2 H) .
• Isomer A first off the column
• isomer B second off column
• They were individually hydrogenated over 10% Pd/C in ethanol at atmospheric pressure to afford 299 mg of l-ethoxycarbonylethyl-3-(S)-[(1-carboxy-3-phenyl-1-propyl)amino]perhydroazepin-2-one (Isomer A) and 762 mg of 1-ethoxycarbonylethyl-3-(S)-[(1-carboxy-3-phenyl-1-propyl)amino]perhydro- azepin-2-one (Isomer B).
• the first isomer spontaneously changed from an oil to an amorphous solid (m.p.
• nmr spectrum (CDC1 3 ) showed the aromatic proton singlet at 7.19 ppm, the ethyl quartet at 4.13 ppm, and the methyl doublet (1.27 ppm) superimposed on the ethyl triplet (1.21 ppm).
• the nmr spectrum (CDC1 3 ) of the second isomer showed the aromatic proton singlet at 7.26 ppm, the ethyl quartet at 4.19 ppm, the methyl doublet at 1.37 pm, and the ethyl triplet at 1.23 ppm.
• the second phthalimide diacid described in Exmple 14 may be converted to 1-carboxyethyl-3-(S)-[(5-amino-l-carboxy-l-pentyl)amino]-perhydroazepin-2-one.
• Methyl 3-(p-phydroxyphenyl)-2-oxopropionate and a-t-Boc-L-lysine are condensed in the presence of sodium cyanoborohydride as described in Example 19. Subsequent ring closure, saponification of methyl ester, and removal of the t-butoxycarbonyl group with formic acid gives 3-(S)-amino-1-[1-carboxy-2-(4-hydroxyphenyl)ethyl]perhydroazepin-2-one.
• caprolactam and 2-oxo-4-phenylbutyric acid are condensed in the presence of sodium cyanoborohydride to yield 1-[1-carboxy-2-(4-hydroxyphenyl)ethyl]-3-(S)-[(1-carboxy-3-phenylpropyl)amino]perhydroazepin-2-one.
• Methyl 2-oxo-3-phenylpropionate and a-t-Boc-L-lysine are condensed in the presence of sodium cyanooorchydride as descrioed in Example 19.
• Subsequent ring closure to 3-(S)-t-butoxycarbonylamino-1-[1-carbomethoxy-2-phenylethyl]perhydroazepin-2-one is carried out as described in Example 3. Saponification of the methyl ester followed by removal of the t-butoxycarbonyl group affords 3-(S)-amino-l-[l-carboxy-2-phenylethyl]perhydroazepin-2-one.
• caprolactam and 2-oxo-4-phenylbutyric acid are condensed in the presence of sodium cyanoborohydride to yield 1-[1-carboxy-2-phenylethyl]-3-(S)-[(1-carboxy-3-phenylpropyl)amino]perhydroazepin-2-one.
• a solution of 850 mg of this aminolactam, 2.14 g ethyl 2-oxo-4-phenylbutyrate and 267 mg sodium acetate is prepared in 8 ml ethanol.
• a solution of 490 mg sodium cyanoborohydride in 3 ml ethanol is added over 3.5 hr and stirring is continued overnight.
• the reaction is filtered and concentrated and the residue is partitioned between ethyl acetate and 5% sodium bicarbonate. The organic phase is washed with brine, dried and concentrated.
• This compound was made from the corresponding ethyl ester by a method similar to that described in the foregoing Example.
• Racemate A (first to elute).
• Racemate B (second to elute).
• Anal. Calc. (C 25 H 38 N 2 O 5 ) : C, 67.24; H, 8.58; N , 6. 27 . Found: C, 66.82; H, 8.55; N, 6.10. Mass spectrum: same as above.
• Mass spectrum M + 390, m/e: 373 (M + -OH); 362 (M + - C 2 H 4 ); 331 (M + - CH 2 CO 2 H); 317 (M + -CO 2 C 2 H 5 ).
• racemate B monoester trifluoroacetate in 2.5 ml. 1N NaOH and store the solution for 18 hr. at room temperature. Apply the reaction mixture to a column of Dowex 50 (H + ), elute first with H 2 0 and then with 5% pyridine. Combine and concentrate the appropriate fractions and isolate 1-carboxymethyl-3-[(1-carboxy-3-phenylpropyl)amino]-7-methylperhydroazepin-2-one (racemate B), m.p. 215-217° Dec.
• Mass spectrum M + 362; m/e: 344 (M + -H 2 0), 318 (M - CO 2 ) ; 317 (M - CO 2 H).
• Mass spectrum M + 362; m/e: 344 (M + -H 2 O) ; 318 (M + -CO 2 ) ; 317 (M + -CO 2 H) .
• the isomers of 1-carboxymethyl-3-[(1-ethoxycarbonyl-3-phenylpropyl)amino]-7-methyl aerhydroazepin-2-one may each be converted to the corresponding diethyl esters by the method described in Example 22.
• Each of the isomeric esters is hydrolyzed in dilute sodium hydroxide.
• the hydrolysate is chromatographed over acidic ion exchange resin eluting with 5% pyridine in water. Concentration of the appropriate fractions affords the respective isomers of 1-(1-carboxyethyl)-3-(S)-[(1-carboxy-3-phenylpropyl)amino]perhydroazepin-2-one.
• Example 24 The diastereomers described in Example 24 are catalytically dibenzylated over palladium on carbon in aqueous dioxane to afford the respective diastereomers of 1-(1-carboxyethyl)-3-(S)-(1- ethoxycarbonyl-3-phenylpropyl)aminoperhydroazepin-2- one.
• sodium cyanoborohydride may be used in the reductive condensation as described in Example 24.
• Diacids of Formula I derived from 3-(S)-amino-1-(1-carboxyethyl)perhydroazepin-2-one
• Diacids of Formula I derived from 3-amino-1-carboxymethyl-7-methylperhydroazepin-2-one
• the t-butyl ester of the major diastereomer of 3-amino-l-t-butoxycarbonylmethyl-7-methylperhydroazepin2-one may be cleaved with trifluoroacetic acid to afford 3-amino-l-carboxymethyl-7-methylperhydroazepin-2-one.
• Reductive condensation of this compound with the a-ketoacids listed in Table III following the procedure described in Example I affords the products of Formula I described above.
• a typical tablet contains 1-(1(S)-carboxyethyl)-3-(S)-[(1(S)-ethoxycarbonyl-3-phenylpropyl)-amino]perhydroazepin-2-one (25 mg.), pregelatinized starch USP (82 mg.), microcrystalline cellulose (82 mg.) and magnesium stearate (1 mg.).
• 1-(1(S)-carboxyethyl)-3-(S)-[(1(S)-carboxy-5-amino-1-pentyl)amino]perhydroazepin-2-one (20 mg.) may be formulated in place of 1-(1(S)-carboxyethyl)-3-(S)-[(1(S)-ethoxycarbonyl-3-phenylpropyl)amino]perhydroazepin-2-one with the composition of pregelatinized starch, microcrystalline cellulose and magnesium stearate described above.
• Dry filled capsule containing 5 mg. of active ingredient.

Applications Claiming Priority (4)

Publications (3)

Family

ID=26875204

Family Applications (1)

Country Status (6)

Cited By (20)

Citations (3)

• 1981
  • 1981-08-14 GR GR65798A patent/GR74635B/el unknown
  • 1981-08-17 ES ES504791A patent/ES504791A0/es active Granted
  • 1981-08-17 EP EP19810106372 patent/EP0046291B1/de not_active Expired
  • 1981-08-17 DE DE8181106372T patent/DE3173304D1/de not_active Expired
  • 1981-08-17 DK DK364181A patent/DK364181A/da not_active Application Discontinuation
  • 1981-08-18 PT PT7353781A patent/PT73537B/pt unknown
• 1983
  • 1983-01-17 ES ES519057A patent/ES519057A0/es active Granted

Patent Citations (3)

Also Published As

Similar Documents

Legal Events